Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 17/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 17/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211471 | 0.87 | NOTUM (0.64) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL14302898 | 0.80 | NOTUM (0.71) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL19219546 | 0.79 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19219548 | 0.76 | RXRA (0.84) | RXRAGRIN1GRIN2B | |
| SCHEMBL20468184 | 0.74 | NOTUM (0.72) | RXRAGRIN1GRIN2BNOTUMKCNH2 | |
| SCHEMBL19219547 | 0.73 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL13255707 | 0.72 | NOTUM (0.54) | RXRAGRIN1GRIN2BNOTUMKCNH2 | |
| SCHEMBL25165158 | 0.71 | RXRA (0.56) | RXRAGRIN1GRIN2BNOTUMKCNH2 | |
| SCHEMBL17666326 | 0.71 | RXRA (0.51) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL19211358 | 0.71 | NOTUM (0.68) | RXRAGRIN1GRIN2BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | RXRA 268/4885GRIN1 2647/4885GRIN2B 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.